Merck introduces Aptegra CHO genetic stability assay for accelerated biosafety testing

NewsGuard 100/100 Score

Merck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind. The Aptegra CHO genetic stability assay leverages whole genome sequencing and bioinformatics to significantly accelerate biosafety testing for clients and therefore, their move into commercial production.

Merck Introduces Aptegra CHO genetic stability assay for accelerated biosafety testing
A scientist preparing samples in the next-generation sequencing laboratory at Merck’s/MilliporeSigma’s Rockville, Maryland, USA site. Image Credit: Merck

Driving innovation in biosafety testing is essential to bringing new therapies to patients faster. CHO genetic stability testing has remained relatively unchanged for many years. The Aptegra platform transforms biosafety testing with a digital solution using next-generation sequencing."

Benjamin Hein, Head of Life Science Services, Life Science business of Merck

Currently, FDA guidance requires biotech companies to use multiple assays to address genetic stability requirements. This traditional package of assays is costly, time-consuming, and often results in data that need additional interpretation and support. The Aptegra platform addresses these pain points by replacing five different assays and four different technologies with one assay utilizing the next-generation sequencing technology platform. This approach reduces testing time by 66 percent and reduces costs by 43 percent compared to traditional methods. The platform meets all regulatory requirements for genetic stability assurance, including copy number assessment.

Merck has made significant investments over the last five years to expand its biosafety testing capabilities for clients across the globe. The company's global biosafety testing network includes sites in Shanghai, China; Singapore; Stirling and Glasgow, UK; and Rockville, MD, USA.

The Aptegra digital platform adds to a transformative portfolio of digital technologies developed by Merck. In December, Merck launched AIDDISON™, an AI-powered platform that integrates generative design with predictive synthesis planning, allowing rapid identification of promising candidates and reducing risk of late-stage failures. Additionally, Merck offers a first of its kind Bio4C® Software Suite, which combines data analytics and visualization, automation, and control software for GMP manufacturing.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Genetic variant increases heart failure risk and decreases longevity in Black Americans